Navigation Links
Sopherion Therapeutics Secures $55 Million in Series C Funding
Date:2/19/2009

PRINCETON, N.J., Feb. 19 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, has announced a $55 million Series C financing. The financing was led by Zoticon Bioventures, a global drug development and healthcare investment firm.

The company will use the funding to complete the pivotal Phase III clinical development program for its lead product candidate, Myocet(TM). Myocet is a liposomal formulation of doxorubicin designed to reduce the risk of cardiotoxicity while preserving antitumor efficacy.

In January 2008, Zoticon Bioventures in-licensed Myocet and provided funding of $20 million to Sopherion and subsequently led an additional $35 million raise during 2008. Proceeds are to fund Sopherion and complete its global, registrational trial of Myocet in combination with trastuzumab and paclitaxel vs. trastuzumab and paclitaxel for first-line therapy of patients with metastatic breast cancer. Additional investors in the $35MM round include TL Ventures, New Leaf Venture Partners/Sprout Group, ProQuest Investments, Canaan Partners, Devon Park Bioventures, Commerce Bank and NewSpring Capital.

"This funding is an important milestone for Sopherion and represents continued validation for Myocet, which we believe has the potential to become the standard of care for patients with advanced breast cancer when used in combination with trastuzumab and paclitaxel," said Ronald H. Goldfarb, Ph.D., President and CEO of Sopherion Therapeutics. "Zoticon's experience in biotech is a great asset for us, and we look forward to continuing to work closely together."

"Zoticon is very excited to be involved with Sopherion and the Myocet program in North America. This investment underscores our strong, continued belief in the significant advances the company is contributing to the field of oncology and to addressing significant unmet medical needs," said Asher Nathan, Managing Director of Zoticon and Chairman of the Board, Sopherion Therapeutics, LLC.

About Sopherion Therapeutics, LLC

Sopherion Therapeutics, LLC is a privately-held biotechnology company based in Princeton, New Jersey. The Company is focused on developing novel anti-cancer therapies for patients suffering from advanced cancer, particularly metastatic disease. Sopherion is dedicated to the acquisition, discovery, development and commercialization of novel anti-cancer therapies with unique therapeutic activities that address unmet medical needs in and extend human life. In 2004, Sopherion entered into an exclusive licensing agreement with Zeneus Pharma Ltd., now Cephalon, Inc. for the future commercialization of Myocet in North America. For more information, visit www.sopherion.com.

About Zoticon Bioventures

Zoticon is a privately held global drug development and healthcare investment firm with a portfolio of life-sciences-focused companies. Zoticon's business model is to in-license novel therapeutics, and continue their clinical development. For more information, visit www2.zoticon.com.


'/>"/>
SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
4. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
5. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
6. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
7. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
8. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
9. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
11. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... SAN DIEGO , Dec. 8, 2016 /PRNewswire/ ... presented demonstrating the role of the Breast Cancer ... stage, ER+ breast cancer are most at-risk for ... therapy. Data include results from three studies advancing ... provide information related to tumor biology and inform ...
(Date:12/8/2016)... 8, 2016 Eurofins announces the appointment of Sean ... Eurofins Scientific Inc. (ESI). Mr. Murray will bring ... and entrepreneurial experience in leading international business teams. As the National ... market to uphold Eurofins, status as the global leader in bio-analytical ... , , ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... FrontPanel SDK that provide essential device-to-computer interconnect using USB or PCI Express, announced ... FrontPanel support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits a ...
(Date:12/8/2016)... 2016 Oxford Gene Technology ... NGS panel range with the launch of the SureSeq myPanel™ ... of variants in familial hypercholesterolemia (FH). The panel delivers single ... a single small panel and allows customisation by ,mix and ... exons for LDLR , P C ...
Breaking Biology Technology:
(Date:11/22/2016)... MINNETONKA, Minn. , Nov. 22, 2016   ... that supports the entire spectrum of clinical research, is ... by Medical LiveWire Healthcare and Life Sciences Awards ... This award caps off an unprecedented year of recognition ... clinical trials for over 15 years. iMedNet ...
(Date:11/17/2016)... 2016  AIC announces that it has just released a new white paper authored ... scale-out plus high speed data transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system ...
(Date:11/14/2016)...  xG Technology, Inc. ("xG" or the "Company") (Nasdaq: ... for use in challenging operating environments, announced its results ... will hold a conference call to discuss these results ... (details below). Key Recent Accomplishments ... agreement to acquire Vislink Communication Systems. The purchase is ...
Breaking Biology News(10 mins):